Cough syrup crisis: Tamil Nadu suspends 2 drug inspectors, moves to close pharma co

Published On 2025-10-09 10:15 GMT | Update On 2025-10-09 10:15 GMT

Suspended

Chennai: Two senior drug inspectors have been suspended for their inaction in the deadly cough syrup adulteration case that has claimed multiple lives, Tamil Nadu Health Minister Ma Subramanian said.

The inspectors were served notice for failing to inspect the Sresen Pharma manufacturing facility for two years. In light of this, they were suspended from their positions.

As per PTI, the minister also confirmed that steps will be taken to permanently shut down the pharma company whose product allegedly claimed many lives.

"Tamil Nadu was the first to confirm the adulteration in the cough syrup (Coldrif) and we immediately informed the Union Health Ministry, Madhya Pradesh, Odisha, and even Puducherry about the health hazard of consuming the cough syrup," Subramanian told reporters here when his attention was drawn to the arrest of Sresen Pharma company owner G Ranganathan, today.

Immediately, the state government issued "stop production" order on October 3 and temporarily revoked the company’s manufacturing licence. Criminal action was initiated on Ranganathan on October 7, and he was arrested past midnight on October 8, he said.

"Based on a detailed investigation, which is underway, steps will be taken to permanently close down the pharma company. A decision will be taken in three days’ time," the minister assured.

Also, Subramanian informed that the state stopped procuring Coldrif following the “adulteration” and had even banned its sale in the market. "Due to our prompt action, a major catastrophe was averted," he added.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Cough syrup crisis: Tamil Nadu suspends 2 drug inspectors, moves to close pharma co

Similar News

3 cough syrups recalled, none exported: CDSCO responds to WHO

SC to hear plea seeking CBI probe into cough syrup deaths on October 10

TN based cough syrup pharma owner arrested in Chennai

Stop using these cough syrups immediately, warns Telangana Drug Authority

Lupin plans to build new pharma manufacturing plant in Coral Springs

Abbott India appoints Tushar Singh as Plant Director - Goa

After Cough Syrup Deaths, CDSCO Tightens Oversight on Drug Testing Compliance